GALE Galenica AG
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic services; and develops, markets, and sells healthcare services and products through various distribution channels. The Logistics & IT segment provides various specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers master data systems for the healthcare market; develops management solutions for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products, as well as offers complete management solutions for pharmacies. In addition, it provides on-schedule delivery services to pharmacies, drugstores, doctors, hospitals, and care homes. The company was founded in 1927 and is headquartered in Bern, Switzerland.…
Industry Peers
Medical DistributionKey Statistics
About Galenica (SWX: GALE)
›
Galenica (SWX: GALE) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 6,623 employees.
The shares were at 89.60 CHF on 20 November 2026, up 6.7% over 52 weeks. Its 52-week range is 80.40 CHF to 103.00 CHF: the price is 13.0% below the high and 11.4% above the low.
At a market capitalisation of 4.46B CHF, it trades at 27.7 times trailing earnings and 21.1 times forward earnings. The median trailing P/E of its 17 largest Medical Distribution peers is 19.9, a premium of 39% for GALE. It pays a dividend yielding 2.82% (it pays out 77% of its earnings), against a median of 1.38% among the dividend payers in that peer group.
Galenica reports return on equity of 12.2%, an operating margin of 4.8% and revenue up 7.0% year over year.
Its debt exceeds its cash by 1.07B CHF, a debt-to-equity ratio of 0.16. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Hold; their mean price target of 90.20 CHF is 0.7% above the current price. The next earnings report is expected on 9 March 2027.